

Celltrion Healthcare Australia Pty Ltd Suite 13.03, 31 Market Street Sydney, NSW 2000

10th March 2022

Suppy Shortage of OGIVRI®(trastuzumab) 150mg Vials

Dear Health Care Professional / Customer

We refer to the supply shortage of OGIVRI® brand trastuzumab 150mg, reported on the TGA - Medicine Shortage Report Data Base per link below. In view of this development, Celltrion Healthcare - Australia and our commercial partner Echo Therapeutics wish to confirm that adequate stocks of Herzuma® brand trastuzumab 150mg are available for supply to hospitals to minimize any impact to patient care, with this important oncology medication.

https://apps.tga.gov.au/Prod/msi/search?shortagetype=All

Please reach out to Jude D'Silva from Echo Therapeutics (Mobile: 0417 944 428) for any assistance with stock supply and/or questions you may have regarding this communication

Thanking you

Anthony Botelu

Head of Marketing – Celltrion Healthcare Australia